Possibility of atorvastatin 20 mg/d in patients of acute coronary syndrome in early stage

[Objective] To investigate the safety and efficacy of atorvastatin 20 mg/d to treat patients with acute coronary syndrome(ACS) in early stage.[Methods] The patients with ACS were randomly divided into: group 1(n=54) given atorvastatin 20 mg/d and group 2(n=53)10 mg/d at night,and the efficacy,the incidence of cardiovascular events and adverse reaction of the drug therapy were recorded in 6 months follow up.[Results]For group 1 and group 2,in 6 weeks after the treatment,the decreasing rates of the total plasma cholesterol(TC) were 34.3% and 24.7%,the decreasing rates of triglyceride(TG) 30.9% and 23.2%,the decreasing rates of low density lipoprotein(LDL-C) 32.4% and 25.3%,increasing rates of high density lipoprotein(HDL-C) 9.7% and 5.4%,;in 6 months after treatment,the decreasing rates of TC were while 37.9% and 30.6%,decreasing rates of TG 38.5% and 25.1%,decreasing rates of LDL-C 49.1% and 29.9%,while increasing rates of HDL-C 16.8% and 10.7%,there were significant difference between the each pair(P0.05).Of group 1 and group 2 in 6 weeks after treatment,rates reaching to target of total blood-lipid goal level were 55.6% and 41.9%,on TC were 64.7% and 49.6%,LDL were 66.1% and 48.1%;in 6 months,rates reaching to target of total blood-lipid goal level were 62.1% and 44.1%,on TC were 72.5% and 52.2%,LDL were 71.2% and 51.1%,there were significant difference between each pair(P0.05).Comparing with group2 there were relatively lower recurrent rates of angina pectoris,congestive heart failure and arrhythmia occurrence in group1 during hospitalization(P0.05).There were significantly lower recurrent rates of angina pectoris,congestive heart failure,non-failure myocardial infarction,recanalization therapy with percutaneous transluminal coronary angioplasty (PTCA) or with coronary artery bypass surgery(CABG) and re-hospitalization in group1 during the 6 months following up(P0.05).The drug adverse reaction was not significantly different between two groups.[Conclusions] The early use of atovastatin in dose of 20mg/d will be possible in safety,efficacy and tolerance.